Read more
This book comprehensively explores the latest advancements in multi-omics strategies for diagnosing gallbladder cancer. The initial section delves into the genetic mutations and molecular pathways critical for the onset and progression of gallbladder cancer. Through targeted gene sequencing and genomic profiling, it identifies both somatic and rare germline mutations, pinpointing driver genes and predisposing mutations. The subsequent section examines the proteins and molecular pathways altered in gallbladder cancer. It uncovers dysregulated proteins, identifies tumor biomarkers, and evaluates circulating markers for early detection. The book further investigates the impact of infections like
Salmonella enterica of the serotypes Paratyphi A on gallbladder tissue, revealing genotoxic effects and potential biomarkers. It also explores the correlation between the gallbladder microbiome, physiological state, and biliary metabolic profile. Towards the end, the book introduces cutting-edge techniques like machine learning-based CT imaging for survival prediction and examines the role of epigenetic pathways and non-coding RNAs in gallbladder cancer. This section also discusses the potential of targeting mTOR pathways and the significance of inflammatory and immune markers, offering a glimpse into the future of gallbladder cancer diagnosis and treatment. This book is a valuable resource for oncologists and researchers working in the fields of oncology, genomics, proteomics, metabolomics, bioinformatics, molecular biology, and translational medicine.
List of contents
Chapter 1: Gallbladder Carcinoma: Estimation of Risk Factors and Identification of Prognostic FeaturesChapter 2: Molecular Genetics of Gallbladder Cancer Chapter 3: The Genetic Blueprint of Gallbladder Carcinogenesis: Advances and Discoveries Chapter 4: Genomic Insights in Gallbladder Cancer: Molecular Alterations and Single Polymorphism nucleotides associated with ancestry Chapter 5: Molecular Genetics Alteration and its Prognostic Significance in Gallbladder CarcinogenesisChapter 6: Role of Metabolomics in Carcinoma Gallbladder Chapter 7: Metabolomics Approach to Understanding Gallbladder Cancer Progression Due to Gallstone Disease Chapter 8: Metabolomics: A Potential Biomarkers in Gallbladder CarcinogenesisChapter 9: Long noncoding RNAs (lncRNAs)Chapter 10: Metabolic Reprogramming in Gallbladder CancerChapter 11: Insights and Innovations in Gallbladder Carcinogenesis Chapter 12: Leveraging Artificial Intelligence and Multi-Omics in Gallbladder Cancer Diagnosis and Management Chapter 13: Proteomic Insights in Gallbladder Cancer: Techniques for Biomarker IdentificationChapter 14: Molecular Profile of Gallbladder Cancer
About the author
Dr. Vijay Kumar Shukla is the Ex-Rector of Banaras Hindu University and Former Professor of General Surgery at the Institute of Medical Sciences, BHU, Varanasi. Internationally recognized for his work in gallbladder cancer and wound healing, he has published over 380 research papers and served as a Visiting Professor at reputed international institutions. He has received numerous awards, including the Lifetime Achievement Award by the World Union of Wound Healing Societies (Toronto, 2008), and fellowships from NAMS and FCWCS, Malaysia. Dr. Shukla has held several key positions, including President of the Indian Society of Wound Management, Member of the ICMR Task Force on Gallbladder Cancer, and Governing Council Member of ASI, contributing extensively to academic leadership and healthcare policy.
Dr. Manoj Pandey is a Professor in the Department of Surgical Oncology at the Institute of Medical Sciences, Banaras Hindu University (BHU), Varanasi. A renowned expert in gallbladder cancer research, Dr. Pandey's dedication to advancing cancer care is evident through his extensive body of work, comprising over 357 scientific publications in reputed journals. He has been honored with several prestigious awards, including the Dr. U. C. Gupta Memorial Award for Excellence in Surgery. He has also served as a member of the ICMR task force for the review of cancer management in India. Dr. Pandey currently serves as the Principal Investigator (PI) for both the Health Technology Assessment in India (HTAIn) Resource Centre and the DIAMOnDS project, highlighting his pivotal role in evidence-based healthcare and translational research at the national level.
Dr. Ruhi Dixit is currently serving as Scientist-C at the Health Technology Assessment India (HTAIn) Resource Centre, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. She has a strong research interest in cancer biology, particularly gallbladder cancer, and has made notable contributions to the field through her work on genomic and molecular biomarkers. Alongside her cancer research, she is also actively engaged in Health Technology Assessment (HTA) projects, contributing to evidence-based healthcare policy and decision-making. Dr. Dixit has authored several publications in high-impact, peer-reviewed international journals, and serves as both editor and reviewer for reputed double-blind international journals, reflecting her academic integrity and active involvement in the global scientific community.
